BDNF Release and Signaling are Required for the Antidepressant Actions of GLYX-13

Conventional antidepressant medications, which act on monoaminergic systems, display significant limitations, including a time lag of weeks to months and low rates of therapeutic efficacy. GLYX-13 is a novel glutamatergic compound that acts as an NMDA modulator with glycine-like partial agonist prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Taro, Fogaça, Manoela V., Deyama, Satoshi, Li, Xiao-Yuan, Fukumoto, Kenichi, Duman, Ronald S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988860/
https://www.ncbi.nlm.nih.gov/pubmed/29203848
http://dx.doi.org/10.1038/mp.2017.220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988860/
https://www.ncbi.nlm.nih.gov/pubmed/29203848
http://dx.doi.org/10.1038/mp.2017.220

Ejemplares similares